Skip to main content
SpringerLink
Log in

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Objective

Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment.

Methods

Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug.

Results

Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN.

Conclusion

The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076

    CAS  PubMed  Google Scholar 

  2. Nawrocki ST, Carew JS, Dunner K, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ (2005) Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 65:11510–11519

    Article  CAS  PubMed  Google Scholar 

  3. Shao L, Wang S, Meng H, Qian W, Mai W, Yu W, Tong H, Mao L, Wei J, Qian J, Jin J (2015) Bortezomib-induced peripheral neuropathy in multiple myeloma patients. Zhonghua Yi Xue Za Zhi 95:3297

    PubMed  Google Scholar 

  4. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine D, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  CAS  PubMed  Google Scholar 

  5. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine D, Schenkein DP, Anderson KC (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127:165–172

    Article  CAS  PubMed  Google Scholar 

  6. Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27–46

    Article  CAS  PubMed  Google Scholar 

  7. Voorhees PM, Dees EC, O’Neil B, Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316–6325

    CAS  PubMed  Google Scholar 

  8. Jackson G, Einsele H, Moreau P, Miguel JS (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 31:591–602

    Article  CAS  PubMed  Google Scholar 

  9. Khan RZ, Badros A (2012) Role of carfilzomib in the treatment of multiple myeloma. Expert Rev Hematol 5(4):361–372

    Article  CAS  PubMed  Google Scholar 

  10. Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M (2015) Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33:113–119

    Article  CAS  PubMed  Google Scholar 

  11. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120

    Article  CAS  PubMed  Google Scholar 

  12. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042–1049

    Article  CAS  PubMed  Google Scholar 

  13. Bang S, Lee JH, Yoon S, Park S, Min C, Kim C, Suh C, Sohn SK, Min Y, Lee J, Kim K, Seong C, Yoon H, Cho KS, Jo D, Lee KH, Lee N, Kim CS (2006) Korean multiple myeloma working party 2006. A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma International Journal of Hematology 83:309–313

    CAS  PubMed  Google Scholar 

  14. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ (2009) Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 84:657–660

    Article  CAS  PubMed  Google Scholar 

  15. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS (2008) Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clinical advances in hematology & oncology: H&O 6:755–760

    Google Scholar 

  16. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K (2005) Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 104:2141–2148

    Article  CAS  PubMed  Google Scholar 

  17. Knopf KB, Duh MS, Lafeuille M, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL (2014) Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clinical lymphoma, myeloma & leukemia 14:380–388

    Article  Google Scholar 

  18. Durie BGM, Harousseau J, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473

    Article  CAS  PubMed  Google Scholar 

  19. Ciolli S, Leoni F, Casini C, Bosi A (2007) Feasibility and efficacy of bortezomib retreatment in multiple myeloma. Haematologica 92:95 Abstract 0260

    Article  Google Scholar 

  20. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA (2008) An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 8:140–145

    Article  CAS  PubMed  Google Scholar 

  21. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649–659

    Article  CAS  PubMed  Google Scholar 

  22. Oriol A, Giraldo P, Kotsianidis I, Couturier C, Olie R, Angermund R, Corso A (2015) Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: a retrospective study. Hematology (Amsterdam, Netherlands) 20:405–409

    CAS  Google Scholar 

  23. El-Cheikh J, Stoppa A, Bouabdallah R, de Lavallade H, Coso D, de Collela JS, Auran-Schleinitz T, Gastaut J, Blaise D, Mohty M (2008) Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma 8:146–152

    Article  CAS  PubMed  Google Scholar 

  24. Nooka AK, Kastritis E, Dimopoulos MA, Lonial S (2015) Treatment options for relapsed and refractory multiple myeloma. Blood 125:3085–3099

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncotherapeutics, West Hollywood, CA, USA

    Aleksandra P. Vidisheva, Tanya M. Spektor & James R. Berenson

  2. James R. Berenson, MD, Inc., West Hollywood, CA, USA

    James Wang, Regina A. Swift, Tina M Maluso, Kyle A Udd, Shahrooz Eshaghian, Youram Nassir & James R. Berenson

  3. Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA

    James Wang & James R. Berenson

  4. Oncology Specialist Research Institute, Park Ridge, IL, USA

    Jacob D Bitran

  5. Mount Sinai Medical Center, Miami Beach, FL, USA

    Jose Lutzky

  6. George Washington University, Washington, DC, USA

    Imad A. Tabbara

  7. Vista Oncology, Olympia, WA, USA

    Joseph Z. Ye

  8. University of Southern California, Los Angeles, CA, USA

    Sikander Ailawadhi

  9. Pacific Cancer Care, Monterey, CA, USA

    Laura V. Stampleman

  10. Atlanta Cancer Care, Atlanta, GA, USA

    Ronald G. Steis

  11. Cancer Specialists of North Florida, Jacksonville, FL, USA

    Mehdi M. Moezi

Authors
  1. Aleksandra P. Vidisheva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanya M. Spektor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jacob D Bitran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jose Lutzky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Imad A. Tabbara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joseph Z. Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sikander Ailawadhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laura V. Stampleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ronald G. Steis
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mehdi M. Moezi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Regina A. Swift
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tina M Maluso
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kyle A Udd
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shahrooz Eshaghian
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Youram Nassir
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. James R. Berenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James R. Berenson.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Retrospective study

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vidisheva, A.P., Wang, J., Spektor, T.M. et al. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Support Care Cancer 25, 3217–3224 (2017). https://doi.org/10.1007/s00520-017-3732-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-017-3732-6

Keywords

Search

Navigation